Clint T. Allen, M.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10 - Clinical Center, Room 7N240C
- Bethesda, MD 20892
Dr. Allen’s research centers on immunologic aspects of head and neck cancer and neoplasm development, progression and treatment. Dr. Allen leads a scientific laboratory and clinical research program that focuses on developing novel treatment approaches for human papillomavirus (HPV)-positive and -negative head and neck squamous cell carcinoma as well as recurrent respiratory papillomatosis (RRP). Through close relationships with academic partners in the National Capitol Region community and throughout the country, Dr. Allen maintains a robust referral network for patients interested in prospective immunotherapy clinical trials for newly diagnosed head and neck cancer and RRP.
American Board of Otolaryngology
Areas of Expertise
Current standard of care treatments for head and neck cancer unrelated to human papillomavirus (including oral cavity cancer and larynx cancer) fail to provide long-term cures for many patients. Through the integration of immunotherapy into these treatments based on solid research laboratory evidence, we aim to improve disease-free survival for head and neck cancer patients. The study of tumor biopsies before and after treatment allows our team to understand exactly what is happening to the immune system during these treatments and determine how to optimize these treatments to be as safe and powerful as possible. Our team is also applying important lessons learned from studying these types of cancers to other problematic head and neck neoplasms, such as tonsil cancers, caused by chronic infection with specific types of human papillomavirus (HPV) and recurrent respiratory papillomatosis, caused by other types of HPV. Our comprehensive scientific and clinical research program is one of the few worldwide to study the immunologic aspects of both cancerous and papillomatous lesions of the head and neck.
Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-b blockade in HPV-unrelated head and neck cancer
Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity
Comprehensive multiomic characterization of human papillomavirus-driven recurrent respiratory papillomatosis reveals distinct molecular subtypes
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells
Clint T. Allen, M.D.
Dr. Allen graduated from the Texas A&M Health Science Center College of Medicine and is an alumnus of the Clinical Research Training Program (CRTP) at the NIH Clinical Center. After medical school, he received otolaryngology surgical training at Washington University in St. Louis/Barnes-Jewish Hospital and sub-specialty fellowship training in laryngological surgery at the University of Washington. While maintaining a laryngology practice and faculty position at Johns Hopkins, Dr. Allen’s initial appointment to the NIH was through the National Institute on Deafness and Other Communication Disorders (NIDCD) Otolaryngology Surgeon Scientist Program. After five years of joint Johns Hopkins and NIH faculty appointments, Dr. Allen transitioned to a full-time NIH position within the NIDCD where, in 2020, he was tenured and named Chief of the Section on Translational Tumor Immunology. After serving as Acting Head and Neck Surgery Branch Chief and NIDCD Acting Clinical Director for a period, he transitioned to the Head and Neck Section of the Surgical Oncology Program at CCR. Dr. Allen has received numerous specialty society awards and has authored over 100 peer-reviewed publications.
There are no open positions at this time. Check back again later, or take a look at CCR's Careers page.